These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 10090437

  • 1. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
    Bottorff MB, Yenkowsky JP, Cave DG.
    Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
    [Abstract] [Full Text] [Related]

  • 2. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A, Jovell AJ, García-Altés A, García-Closas R, Serra-Majem L.
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [Abstract] [Full Text] [Related]

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 4. Managed care trends in statin usage.
    Bazalo GR.
    Manag Care; 2001 Oct; 10(10):48-50, 53-9. PubMed ID: 11688111
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [Abstract] [Full Text] [Related]

  • 6. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M, O'Donnell JC, Jones P.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [Abstract] [Full Text] [Related]

  • 7. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
    Rinfret S, Behlouli H, Eisenberg MJ, Humphries K, Tu JV, Pilote L.
    Am Heart J; 2008 Feb; 155(2):316-23. PubMed ID: 18215603
    [Abstract] [Full Text] [Related]

  • 8. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E, Ezetimibe Study Group.
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS, Smith DG, Jones P.
    Am J Cardiol; 2005 Jun 01; 95(11):1314-9. PubMed ID: 15904635
    [Abstract] [Full Text] [Related]

  • 10. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD, Patel H.
    Int J Clin Pract; 2001 May 01; 55(4):243-9. PubMed ID: 11406909
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC.
    Can J Clin Pharmacol; 2001 May 01; 8(1):9-16. PubMed ID: 11283756
    [Abstract] [Full Text] [Related]

  • 12. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z, Rahme E, Pilote L.
    Am Heart J; 2006 Feb 01; 151(2):273-81. PubMed ID: 16442888
    [Abstract] [Full Text] [Related]

  • 13. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
    Smart AJ, Walters L.
    S Afr Med J; 1994 Dec 01; 84(12):834-7. PubMed ID: 7570232
    [Abstract] [Full Text] [Related]

  • 14. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, Kokia E.
    Clin Ther; 2008 Nov 01; 30(11):2167-79. PubMed ID: 19108805
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Nov 01; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 16. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB, Frial T, Miller PS.
    Can J Clin Pharmacol; 2007 Nov 01; 14(2):e205-14. PubMed ID: 17556788
    [Abstract] [Full Text] [Related]

  • 17. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL, Cox ER.
    Am J Manag Care; 2008 Dec 01; 14(12):813-8. PubMed ID: 19067498
    [Abstract] [Full Text] [Related]

  • 18. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
    Perrot JL, Guy C, Bour Guichenez G, Amigues O, Servoz J, Cambazard F.
    Ann Dermatol Venereol; 1994 Dec 01; 121(11):817-9. PubMed ID: 7631993
    [Abstract] [Full Text] [Related]

  • 19. Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
    Lachaine J, Rinfret S, Merikle EP, Tarride JE.
    Am Heart J; 2006 Jul 01; 152(1):164-9. PubMed ID: 16824851
    [Abstract] [Full Text] [Related]

  • 20. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.
    Cooke CE, Hammerash WJ.
    Clin Ther; 2006 Apr 01; 28(4):591-9. PubMed ID: 16750470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.